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Fever in neutropenia (FN) is a potentially life-threatening complication of chemotherapy in
pediatric cancer patients. The current standard of care at most institutions is emergency
hospitalization and empirical initiation of broad-spectrum antibiotic therapy.
Methods
We analyzed in retrospect FN episodes with bacteremia in pediatric cancer patients in a sin-
gle center cohort from 1993 to 2012. We assessed the distribution of pathogens, the in vitro
antibiotic susceptibility patterns, and their trends over time.
Results
From a total of 703 FN episodes reported, we assessed 134 FN episodes with bacteremia
with 195 pathogens isolated in 102 patients. Gram-positive pathogens (124, 64%) were
more common than Gram-negative (71, 36%). This proportion did not change over time (p =
0.26). Coagulase-negative staphylococci (64, 32%), viridans group streptococci (42, 22%),
Escherichia coli (33, 17%), Klebsiella spp. (10, 5%) and Pseudomonas aeruginosa (nine,
5%) were the most common pathogens. Comparing the in vitro antibiotic susceptibility pat-
terns, the antimicrobial activity of ceftriaxone plus amikacin (64%; 95%CI: 56%-72%), cefe-
pime (64%; 95%CI 56%-72%), meropenem (64%; 95%CI 56%-72), and piperacillin/
tazobactam (62%; 95%CI 54%-70%), respectively, did not differ significantly. The addition
of vancomycin to those regimens would have increased significantly in vitro activity to 99%
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for ceftriaxone plus amikacin, cefepime, meropenem, and 96% for piperacillin/tazobactam
(p < 0.001).
Conclusions
Over two decades, we detected a relative stable pathogen distribution and found no relevant
trend in the antibiotic susceptibility patterns. Different recommended antibiotic regimens
showed comparable in vitro antimicrobial activity.
Introduction
The most frequent potentially lethal complication of chemotherapy in pediatric patients with
cancer is fever in neutropenia (FN) [1]. The current management with emergency hospitaliza-
tion and empirical administration of intravenous broad-spectrum antibiotics has decreased
mortality to below 1% in pediatric FN episodes [2]. Bacteremia is detected in approximately
every fourth FN episode [1, 3]. Over the last decades, predominantly Gram-positive pathogens
have been isolated in FN with bacteremia, likely because of increased use of antibiotic prophy-
laxis, introduction of long-indwelling intravascular devices, high-dose chemotherapy-induced
mucositis, and use of antacids and histamine blockers [4]. Still, because of the potentially dev-
astating course of Gram-negative bacteremia, especially Pseudomonas aeruginosa, broad cover-
age of Gram-positive and Gram-negative pathogens is recommended for initial empirical
antibiotic therapy in FN [5]. Because of lower toxicity, and advantages in administration and
price, antibiotic monotherapy with an antipseudomonal beta-lactam or a carbapenem is usu-
ally recommended by recent European [5–7] and American [8] guidelines, which are based on
systematic reviews of observational and randomized trials. A second Gram-negative agent or
glycopeptide may be added in patients who are clinically unstable, if an infection with resistant
bacteria is suspected, or at centers with a high rate of resistant pathogens [5–8]. Antibiotic
resistance has been associated with prolonged bacteremia, increased length of hospitalization
and worse outcome in children with cancer and FN [9, 10].
This study aimed to examine the distribution of pathogens isolated during FN with bacter-
emia, their in vitro antibiotic susceptibility patterns against selected antibiotics, and their
trends over time in a single center retrospective cohort study spanning two decades in a pedi-
atric oncology center using only oral trimethoprim/sulfamethoxazole or inhaled pentamidine
diisethionate antimicrobial prophylaxis.
Material and methods
Study design and patients
This retrospective single-center cohort study was conducted at the Division of Pediatric
Hematology and Oncology, Department of Pediatrics, Inselspital, Bern University Hospital,
University of Bern, Switzerland. All children and adolescents less than 17 years old at diagnosis
of malignancy and treated with chemotherapy from 1993 to 2012 were eligible. Details of
patient identification and the data acquisition process have been published elsewhere [11]. For
this analysis, we only included patients with FN and bacteremia. Information on pathogens
isolated in blood culture and in vitro antibiotic susceptibility patterns were available from the
laboratory database of the local Institute for Infectious Diseases. During the anonymization
process the study time period was divided into 4-year intervals (1993 to 1996, 1997 to 2000,
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2001 to 2004, 2005 to 2008, 2009 to 2012) [11]. This study was approved by the Institutional
Review Board (Direktion Lehre und Forschung, Inselspital Bern; registration number, 13-06-
11; last update, April 02, 2014), including waiver of informed consent. On June 30, 2014, data
were fully anonymized before analysis, in order to comply with the request of the new Swiss
Federal Law on Human Research. Other aspects of subsets of these data have been published
before, specifically, data covering the years 2004 to 2007 [1, 12–15], and 2004 to 2011 [2, 16].
Clinical management
Most patients were treated for their malignancy according to established international phase
III protocols or therapy recommendations. Clinical management regarding prophylaxis and
treatment of FN remained unchanged during the complete study period. All patients received
oral trimethoprim/sulfamethoxazole as primary prophylaxis for Pneumocystis jiroveci. Patients
who did not tolerate oral trimethoprim/sulfamethoxazole were switched to inhaled pentami-
dine diisethionate. No other antibiotic prophylaxis was used [11]. Routine management of
patients with cancer presenting with FN included emergency hospitalization and empiric
broad-spectrum intravenous antimicrobial therapy with ceftriaxone plus amikacin as first-line
therapy. Hemodynamically unstable patients at presentation of FN were treated with cefepime
and amikacin, vancomycin was added if a central venous catheter was present. In patients with
FN persisting for more than 48 hours, and in whom no cause of FN had been identified,
empirical therapy was usually escalated to meropenem and vancomycin [14]. Aerobic and
anaerobic blood cultures were sampled at presentation with FN before starting antimicrobial
therapy. Subsequently, one pair of aerobic and anaerobic blood cultures was taken every 24
hours as long as fever continued or in the presence of shaking chills. Blood cultures were col-
lected from each lumen of an existing central venous catheter or peripheral venous line in
patients that did not have a central venous catheter [14].
Definitions
Neutropenia was defined as an absolute neutrophil count� 0.5 G/L [11]. Until July 8, 2007,
fever was defined as an axillary temperature� 38.5˚C persisting� 2 hours, or a single axillary
temperature� 39.0˚C, thereafter it was defined as a single tympanic temperature� 39.0˚C [2,
11]. In the setting of rising temperatures, the different limits used for the different measure-
ment methods have been shown to be comparable [17]. Intensity of chemotherapy was
described using four group classification according to the severity of myelosuppression and
the expected duration of severe neutropenia, as described previously [11, 18], which is an
extension of an earlier classification with two groups [19]. Several FN episodes per patient
were allowed [11]. Bacteremia was defined by the growth of bacteria in blood culture, irrespec-
tive of the bacterial species. Blood cultures were analyzed by a qualitative automated culture
system (BacT/ALERT1, bio-Mérieux, Geneva, Switzerland) [2]. We used the Kirby-Bauer disk
diffusion test to determine in vitro antibiotic susceptibility. To determine the penicillin and
ceftriaxone minimum inhibitory concentrations of viridans group streptococci (VGS) we used
the Etest1 (bioMérieux, previously AB Biodisk). For in vitro susceptibility testing of vancomy-
cin in Enterococcus spp. a brain heart infusion agar screen plate containing six micrograms of
vancomycin per milliliter was used. During the entire study period, the Clinical and Labora-
tory Standards Institute standards were used at our Institute for Infectious Diseases [16]. Poly-
microbial growth was defined as isolation of different pathogens at the same day of FN
episode. If a pathogen was detected in blood cultures taken after the day of FN diagnosis (day
0), this was defined as subsequent bacteremia. Subsequent bacteremia was further subclassified
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into prolonged bacteremia if the same pathogen was repeatedly detected in blood cultures
taken on different days.
In vitro antibiotic susceptibility patterns. We assessed the in vitro antibiotic susceptibil-
ity patterns of bacteria isolated in blood culture against antibiotics commonly used for empiri-
cal therapy in pediatric FN [5]. We evaluated ceftriaxone plus amikacin, the standard
empirical therapy at the study center, cefepime, meropenem, and piperacillin/tazobactam
monotherapy, as well as the combinations of above therapy regimens with vancomycin. We
considered an antibiotic to be active in vitro if the susceptibility pattern showed full suscepti-
bility to the selected antibiotic and the isolated pathogen did not harbor intrinsic resistance to
the selected antibiotic. We considered combination therapy (e.g. ceftriaxone plus amikacin) to
be active in vitro if the susceptibility pattern showed full susceptibility to at least one of the
antibiotics and did not harbor intrinsic resistance against all antibiotics of combination ther-
apy. Enterococci spp. were considered intrinsic resistant to cephalosporins and carbapenems.
Due to technical difficulties in retrieving data from the microbiology database, results of
susceptibility testing were not available from 1993 to mid 1998. Therefore, we excluded the
time period from 1993 to 1996 and all other isolates without available susceptibility testing
from analysis of in vitro antibiotic susceptibility patterns.
Statistical analysis
We presented continuous variables as median and interquartile range (IQR) and nominal data
as frequencies with 95% confidence intervals (95% CI). We used the exact Kruskal-Wallis Test
to analyze trends over time for nominal data and exact Jonckheere-Terpstra-Test for continu-
ous data with Monte Carlo approximation. We compared the in vitro antibiotic susceptibility
patterns with the Fisher’s Exact Test.
For all statistical analyses, 2-sided P-values below 0.05 were considered significant. The
exact Kruskal-Wallis test and exact Jonckheere-Terpstra test were calculated with StatXact 10
(Cytel Inc., Cambridge, MA USA). All other analyses and plots were done using R 3.3.3 (R
Foundation for Statistical Computing, Vienna Austria).
Results
Patients and FN episodes
In the 20 study years, 800 pediatric patients less than 17 years old with cancer were treated at
the University Children‘s Hospital Bern. 596 (75%) received chemotherapy to treat their
malignancy. Of 703 eligible FN episodes, bacteremia was detected in 148 (21%). Specific infor-
mation on the clinical course was available in 138 (90%) of these episodes [11]. Four (3%) epi-
sodes were excluded from analysis because of duplicate information in one and blood-culture
proven invasive fungal infection due to Candida spp. in three. We thus analyzed 134 FN epi-
sodes with bacteremia caused by 195 bacteria isolated in blood culture in 102 patients (Fig 1).
In total 18 of 102 (18%) patients were registered with two and seven (7%) patients with three
bacteremia episodes.
Clinical characteristics of FN episodes with bacteremia
The proportion of FN episodes with bacteremia did not change over time (p = 0.91). Clinical
characteristics and evolution over time of the 134 FN episodes with bacteremia are presented
in Table 1. Over time, we observed less FN episodes in patients with relapse of malignancy. In
107 of 133 (80%) episodes the combination of ceftriaxone plus amikacin was administered as
initial antibiotic treatment. Switch of antibiotic treatment could include a de-escalation to a
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specific treatment based on the susceptibility testing or escalation to broaden the antibiotic
spectrum like meropenem plus vancomycin. A potentially life-threatening complication (not
otherwise specified) occurred in eight (6%) episodes, in seven (5%) patients were admitted to
the intensive care unit, and in two (1%) children died. Among patients treated on intensive
care unit Gram-negative sepsis with E. coli was found in three (3 of 7, 43%) patients (S1
Table). CoNS bacteremia was detected in one child that died, however, the isolate was sensitive
to ceftriaxone and was only isolated in one blood culture. He finally succumbed to invasive
fungal infection due to Aspergillus fumigatus. The other child died on day 3 with fulminant
VGS sepsis detected on day 0. He received antibiotic treatment with ceftriaxone and amikacin
without treatment escalation, susceptibility testing of the isolate was not performed.
Pathogens in FN episodes
124 (64%, 95% CI 56%-70%) Gram-positive and 71 (36%; 95% CI 30%-44%) Gram-negative
bacteria were isolated in blood culture (Table 2). This proportion did not change over time
(p = 0.26), but we observed a significant change over time in Gram-negative pathogen
Fig 1. Flowchart of FN episodes in pediatric patients with cancer and fever in neutropenia, from 1993 to 2012.
Multiple FN episodes per patient allowed. FN = fever and neutropenia.
https://doi.org/10.1371/journal.pone.0246654.g001
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Table 1. Characteristics of FN episodes with bacteremia in pediatric patients with cancer, from 1993 to 2012.
Time period P valueh
FN episodes with bacteremia of all FN episodes a All 1993–1996 1997–2000 2001–2004 2005–2008 2009–2012
134 of 703 (19%) 19 of 138 (14%) 29 of 137 (21%) 40 of 167 (24%) 32 of 153 (21%) 14 of 108 (13%) 0.91
Patient related characteristics
Female 67 (50%) 6 (32%) 15 (52%) 19 (48%) 20 (62%) 7 (50%) 0.13
Age at FN diagnosisb 0.054
0–3 years 42 (31%) 6 (32%) 5 (17%) 12 (30%) 12 (38%) 7 (50%)
4–7 years 22 (16%) 2 (11%) 5 (17%) 3 (8%) 9 (28%) 3 (21%)
8–11 years 30 (22%) 3 (16%) 12 (41%) 9 (22%) 4 (12%) 2 (14%)
12–17 years 40 (30%) 8 (42%) 7 (24%) 16 (40%) 7 (22%) 2 (14%)
Disease related characteristics
Diagnostic groupb,c 0.12
Acute lymphoblastic leukemia 67 (50%) 11 (58%) 17 (59%) 15 (38%) 18 (56%) 6 (43%)
Acute myeloid leukemia 26 (19%) 2 (11%) 2 (7%) 9 (22%) 9 (28%) 4 (29%)
Non-Hodgkin lymphoma 14 (10%) 1 (5%) 5 (17%) 6 (15%) 1 (3%) 1 (7%)
Solid tumors outside of CNS 20 (15%) 4 (21%) 5 (17%) 7 (18%) 2 (6%) 2 (14%)
Tumors of CNS 7 (5%) 1 (5%) 0 3 (8%) 2 (6%) 1 (7%)
Relapse 29 (22%) 8 (42%) 9 (31%) 4 (10%) 5 (16%) 3 (21%) 0.030
Bone marrow involvement 39 (29%) 7 (37%) 5 (17%) 14 (35%) 10 (31%) 3 (21%) 0.98
Therapy related characteristics
Chemotherapyb,d 0.49
Intensity 1 7 (5%) 0 4 (14%) 2 (5%) 1 (3%) 0
Intensity 2 91 (68%) 16 (84%) 17 (59%) 28 (70%) 22 (69%) 8 (57%)
Intensity 3 34 (25%) 3 (16%) 7 (24%) 10 (25%) 9 (28%) 5 (36%)
Intensity 4 2 (1%) 0 1 (3%) 0 0 1 (7%)
Central venous access device 89 (66%) 11 (58%) 18 (62%) 26 (65%) 21 (66%) 13 (93%) 0.09
Initial intravenous antibiotic treatment with ceftriaxone
+ amikacine
107 (80%) 17 (89%) 25 (86%) 32 (80%) 22 (71%) 11 (79%) 0.08
Switched intravenous antibiotic treatment 60 (45%) 1 (5%) 3 (10%) 24 (60%) 23 (72%) 9 (64%) NDi
Antibiotic treatment at discharged 37 (28%) 9 (47%) 2 (7%) 10 (26%) 11 (34%) 5 (36%) 0.51
Duration of intravenous antibiotic treatment (days)d 10 (9–13) 11 (9–14) 10 (10–11) 11 (10–15) 11 (10–14) 9 (8–11) 0.97i
Duration of total (intravenous + oral) antibiotic treatment (days)d 10 (9–14) 11 (9–14) 10 (10–11) 12 (10–15) 11 (10–14) 9 (9–11) 0.92i
Duration of hospitalisation (days) 10 (5–13) 10 (8–14) 7 (3–10) 12 (5–14) 10 (6–14) 10 (6–14) 0.042i
Bacteremia
Polybacterial growthf 15 (11%) 0 8 (28%) 3 (8%) 4 (12%) 0 0.40
Subsequent bacteremia, any timeg 46 (34%) 11 (58%) 8 (28%) 17 (42%) 7 (22%) 3 (21%) 0.031
Subsequent bacteremia, day 1 or 2g 35 (26%) 9 (47%) 8 (28%) 13 (32%) 5 (16%) 0 0.002
Subsequent bacteremia, beyond day 2g 16 (12%) 3 (16%) 0 7 (18%) 3 (9%) 3 (21%) 0.39
Categorical variables are presented as frequency (%) and continuous variables as median (IQR = interquartile range). Column percentages are presented; percentages
are based on available data for each variable. FN = fever and neutropenia. CNS = central nervous system. ND = not done.
aData of all FN episodes [11].
bPercentages do not sum up to 100% because of rounding differences.
cNo FN with bacteremia in patients with Hodgkin lymphoma.
dChemotherapy intensity was classified in four groups according the severity of myelosuppression to the expected duration of severe neutropenia, the higher the number
the longer.
eData not available for 1 episode.
fPolybacterial growth was defined as isolation of different pathogens at the same day of FN episode.
gSubsequent bacteremia was defined, if pathogens were detected in an episode after day 0. Subsequent bacteremia at different time points per episodes possible, numbers
do not add up.
hExact Kruskal-Wallis-Test (Monte-Carlo approximation) for analyses of trend over time.
iThe coding of switch of antibiotics changed between the period before 2000 and after. Therefore we have not performed statistical analysis.
https://doi.org/10.1371/journal.pone.0246654.t001
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distribution (p = 0.021), mainly due to an increased detection of Klebsiella spp. during the last
time period. (Table 2). If we excluded CoNS, pathogen distribution changed to more Gram-
negative 71 (54%; 95% CI 45%-62%) than Gram-positive 61 (46%; 95% CI 38%-55%) bacteria
(S2 Table).
The majority of pathogens, 134 of 195 (69%) were detected on day 0 only. All 71 Gram-neg-
ative bacteria were isolated in blood cultures taken before day 3, 61 (86%) in the first blood cul-
ture taken on day 0, nine (13%) on day 1, and one (1%) on day 2.
Subsequent bacteremia was detected in 46 of 134 (34%) episodes (Table 1). All 20 bacteria
detected in blood cultures sampled after day 2 were Gram-positive, 17 CoNS, one Enterococcus
faecalis and two other Gram-positive pathogens (Fig 2). Over time, fewer episodes with subse-
quent bacteremia at any time and day 1 or 2 were detected (p = 0.031 and p = 0.002, respec-
tively, Table 1). This time trend remained significant when only considering CoNS if there was
prolonged CoNS bacteremia (28 of 111 (25%), p< 0.001) or when only considering bacteria
isolated before day 3 and excluding all CoNS (18 of 101 (18%), p = 0.002, details not shown).
Prolonged bacteremia was detected in 12 of 134 episodes (9%), caused by CoNS in 10 and
P. aeruginosa in two episodes, none had a fatal outcome. In 15 (11%) episodes polymicrobial
growth was noted in blood culture.
In vitro antibiotic susceptibility patterns against selected antibiotic therapy
regimens
We analyzed in vitro antibiotic susceptibility patterns of 143 of 169 (85%) bacteria isolated in
blood culture between 1997 and 2012. The combination of ceftriaxone plus amikacin was
active in vitro in 64% (92 of 143; 95% CI 56%-72%), cefepime 64% (91 of 142; 95% CI 56%-
Table 2. Bacteria detected in blood culture, from 1993 to 2012.
Time period P valuec
All isolates 1993–1996 1997–2000 2001–2004 2005–2008 2009–2012
n = 195 n = 26 n = 46 n = 61 n = 43 n = 19
Gram-positive bacteria 124 (64%) 21 (81%) 25 (54%) 42 (69%) 26 (60%) 10 (53%) 0.26
CoNS 63 (32%) 10 (38%) 10 (22%) 28 (46%) 9 (21%) 6 (32%) 0.77
S. aureus 5 (3%) 3 (12%) 0 0 2 (5%) 0
VGS 42 (22%) 5 (19%) 11 (24%) 11 (18%) 13 (30%) 2 (11%)
Enterococcus spp. 5 (3%) 1 (4%) 1 (2%) 3 (5%) 0 0
Other Gram-positivea 9 (5%) 2 (8%) 3 (7%) 0 2 (5%) 2 (11%)
Gram-negative bacteria 71 (36%) 5 (19%) 21 (46%) 19 (31%) 17 (40%) 9 (47%)
E. coli 33 (17%) 4 (15%) 12 (26%) 7 (11%) 7 (16%) 3 (16%) 0.021
Klebsiella spp. 10 (5%) 0 1 (2%) 4 (7%) 1 (2%) 4 (21%)
P. aeruginosa 9 (5%) 0 0 4 (7%) 5 (12%) 0
Enterobacter spp. 6 (3%) 0 4 (9%) 2 (3%) 0 0
Other Gram-negativeb 19 (10%) 1 (4%) 8 (17%) 4 (7%) 4 (9%) 2 (11%)
Data are frequency (%). Column percentages are presented; percentages are based on available data for each variable. CoNS = coagulase-negative staphylococci.
VGS = Viridans group streptococci.
aStreptococcus spp. (3), Bacillus spp. (2), Corynebacterium sp. (1), Granulicatella adjacens (1), gram-positive cocci in chains, not otherwise specified (1),Micrococcus
kristinae (1).
bCapnocytophaga spp. (6), Haemophilus influenzae (2), Neisseria spp. (2), Acinetobacter lwoffii (1), Fusobacterium nucleatum (1),Moraxella osloensis (1).
cExact Kruskal-Wallis (Monte-Carlo approximation) test for analyses of trend over time.
https://doi.org/10.1371/journal.pone.0246654.t002
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72%), meropenem 64% (91 of 142; 95% CI 56%-72%), and piperacillin/tazobactam 62% (89 of
143; 95% CI 54%-70%). Adding vancomycin to any empirical antibiotic therapy would have
increased activity to 99% for ceftriaxone plus amikacin (138 of 140; 95% CI: 94%-100%), cefe-
pime (139 of 140; 95% CI: 96%-100%), and meropenem (139 of 140; 95% CI: 96%-100%),
while it would have increased activity to 96% for piperacillin/tazobactam (134 of 140; 95% CI:
91%-98%) (p< 0.001 for all comparisons). No significant trend over time was noted (Fig 3).
The isolates not covered in vitro by ceftriaxone plus amikacin were mostly Gram-positive
bacteria (51 of 52, 98%; 44 CoNS, 4 Enterococcus spp., 3 VGS) and one Gram-negative patho-
gen (P. aeruginosa isolate resistant to Amikacin). None of the respective patients died.
If we excluded CoNS fully sensitive to vancomycin, the antibiotic in vitro susceptibility
rates for the examined antibiotic regimens were increased to 89% for piperacillin/tazobactam,
92% for ceftriaxone plus amikacin, cefepime, meropenem. In combination with vancomycin
in vitro susceptibility rates reached 93% for piperacillin/tazobactam, 98% for ceftriaxone plus
amikacin and 99% for cefepime and meropenem (S1 Fig). No significant trend over time was
noted. Piperacillin/tazobactam was tested in vitro resistant to five E. coli and one Klebsiella
pneumoniae isolates.
In the study period, we did not detect methicillin-resistant Staphylococcus aureus or
extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. Of note, one vanco-
mycin-resistant E. faecalis (but sensitive to amoxicillin, teicoplanin, and norfloxacin) and two
VGS isolates resistant to ceftriaxone (ceftriaxone E Test� 4 μg/ml) were detected. Among E.
coli and Klebsiella spp. 18% and 10%, respectively, were resistant to piperacillin/tazobactam
(Table 3).
Fig 2. Temporal distribution of bacteria detection in pediatric patients with cancer and fever in neutropenia. Each
point represents one isolated pathogen (n = 195) on the day when the blood culture was taken after FN diagnosis. All
positive blood cultures taken during FN episode are shown. FN = fever in neutropenia. CoNS = coagulase-negative
staphylococci. VGS = Viridans group streptococci. Day 0 = day of FN diagnosis. Day 1 = the following calendar day
after FN diagnosis and so forth.
https://doi.org/10.1371/journal.pone.0246654.g002
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Discussion
Over a 20-years observation period in a single tertiary pediatric oncology center, we report a
stable distribution of pathogens and antibiotic susceptibility patterns without emergence of
multi-resistant pathogens in pediatric patients with cancer diagnosed with FN with bacter-
emia. Our results can serve as a proof that in a setting with low antimicrobial resistance rates
in the general population [20], infections with multi-resistant pathogens remain uncommon
in children with cancer.
Comparable to other studies in pediatric patients with cancer and FN [4, 8, 9, 21, 22], we
detected more Gram-positive than Gram-negative pathogens in blood culture, and CoNS was
the most frequent pathogen detected. CoNS also constituted the main pathogen detected in
episodes with subsequent bacteremia. An American study found subsequent bacteremia (day
1–13) only in 4% (four of 95) episodes with persistent fever [23]. Our data support that rele-
vant bacteremia is rarely detected in pediatric patients with cancer and FN after day 3 unless
the patient becomes unstable [23]. While the addition of a glycopeptide to empirical antibiotic
therapy would have led to a better in vitro coverage of isolated bacteria, current guidelines
reserve this for selected patients [5, 6, 8]. The addition of a glycopeptide to initial empirical
antibiotic therapy regimens in FN in patients with cancer is not associated with reduced dura-
tion of fever or a decrease in overall mortality [8], CoNS infections are rarely associated with a
severe disease course [24], and the addition of a glycopeptide to initial therapy in FN has been
associated with more frequent adverse effects [5].
Current guidelines—which were not available at the time of this study—do favor mono-
therapy with an antipseudomonal beta-lactam or a carbapenem as first-line treatment [5–8].
Fig 3. In vitro antibiotic susceptibility patterns of empirical antibiotic therapy in bacteria detected in blood culture, from 1997 to 2012. Points
indicate the point estimate for the percentage of in vitro antibiotic susceptibility for each time period in 143 of 169 isolates with full antimicrobial
susceptibility information. Vertical lines present the 95% CI‘s around the point estimates.
https://doi.org/10.1371/journal.pone.0246654.g003
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Table 3. Results of in vitro antibiotic susceptibility testing in the three most common Gram-positive and Gram-negative bacteria detected in blood culture, from
1997 to 2012.
Bacteria Antibiotic Number of resistant isolates







Viridans group streptococci (n = 37) Penicillin (E Test� 0.12 μg/ml)b 16 (67%)
Penicillin (E Test� 4.0 μg/ml) b 4 (17%)
Ceftriaxone (E Test� 1.0 μg/ml)c 15 (88%)
Ceftriaxone (E Test� 4.0 μg/ml)c 2 (12%)
Enterococcus spp. (n = 4) Ampicillin 1 (25%)
Vancomycin 1 (25%)
Gentamycin high-level resistance 3 (75%)
Streptomycin high-level resistance 3 (75%)
Gram-negative bacteria E. coli (n = 29) Ampicillind 24 (86%)
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In our setting, the in vitro antibiotic susceptibility patterns of ceftriaxone plus amikacin was
comparable to cefepime, meropenem, and piperacillin/tazobactam (with or without CoNS).
However, in one of five episodes with P. aeruginosa bacteremia susceptibility testing revealed
resistance to ceftriaxone and amikacin, whilst the isolate would have been susceptible in vitro
to cefepime, meropenem, and piperacillin/tazobactam.
All Gram-negative pathogens detected in our study were isolated in blood cultures taken
before day 3, underscoring the need for a broad coverage of Gram-positive and Gram-negative
pathogens by empirical therapy regimens for FN in pediatric cancer patients. Similar to other
studies, E. coli was the most prevalent Gram-negative pathogen in our study [22, 25]. While
resistance to piperacillin-tazobactam was more prevalent in our cohort (18%, 5 of 28) than in
the general pediatric population in a comparable setting (7%, 18 of 275) [20], we did not detect
ESBL-producing Enterobacteriaceae infections. This is in contrast to other studies in pediatric
patients with cancer and FN that have reported increased rates of multi-resistant bacterial
infections [9, 10, 22, 25–27].
The strengths of the study are the long observation period and a large number of FN epi-
sodes with bacteremia in a setting without relevant changes in clinical management during the
study period. To the best of our knowledge, our study is the longest observational study exam-
ining the pathogen distribution, the in vitro antibiotic susceptibility patterns and their trends
over two decades in pediatric cancer patients.
Given the retrospective nature of the study, several limitations need to be mentioned. First,
data on in vitro antibiotic susceptibility patterns were not available for some pathogens due to
a change in the data storage system during the study period. Second, clinical data was incom-
plete which prevented us from drawing firm conclusions on reasons and nature of adaption of
antibiotic therapies and classification of pathogens as contaminants. Third, the use of Kirby-
Bauer disk diffusion test might be less sensitive to the detection of changes in susceptibility
rates than determining minimum inhibitory concentrations. However, given the long observa-
tion period of the study, we do not think this affects the interpretation of the results. Fourth,
Table 3. (Continued)
Bacteria Antibiotic Number of resistant isolates









Data are frequency (%).
aData not available for two isolates.
bData not available for 13 isolates.
cData not available for 20 isolates.
dData not available for one isolate.
eData not available for 6 isolates.
fData not available for 5 isolates.
https://doi.org/10.1371/journal.pone.0246654.t003
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several FN episodes per patients were allowed and analyses were not formally corrected for
multiple episodes per patient.
In conclusion, this study showed a stable local distribution of pathogens causing bacteremia
during FN episodes in pediatric cancer patients with FN over a 20-years period. The currently
used empirical treatment, with its advantage of once daily application, had an in vitro activity
that was comparable to other recommended treatment regimens and was stable over time. In
our setting, a fourth-generation cephalosporin would be preferred as antipseudomonal mono-
therapy, given the lack of ESBL-resistance and the relatively high rate of resistance against




S1 Table. Episodes with fatal outcome or need of intensive care unit.
(DOCX)




We thank the Swiss Childhood Cancer registry for helping us to identify patients, and S.
Wicki, MD, A. Keisker, MD, P. Binz, MD, R. Ammann, D. Ammann and N. Amport, RN, for
support in data acquisition over the two decades.
Author Contributions
Conceptualization: Roland A. Ammann, Sara Droz.
Formal analysis: Melina Stergiotis, Roland A. Ammann, Philipp Kwame Abayie Agyeman.
Investigation: Melina Stergiotis, Roland A. Ammann, Sara Droz, Christa Koenig, Philipp
Kwame Abayie Agyeman.
Writing – original draft: Melina Stergiotis, Roland A. Ammann, Philipp Kwame Abayie
Agyeman.
Writing – review & editing: Melina Stergiotis, Roland A. Ammann, Sara Droz, Christa Koe-
nig, Philipp Kwame Abayie Agyeman.
References
1. Luthi F, Leibundgut K, Niggli FK, Nadal D, Aebi C, Bodmer N, et al. Serious medical complications in
children with cancer and fever in chemotherapy-induced neutropenia: results of the prospective multi-
center SPOG 2003 FN study. Pediatric blood & cancer. 2012; 59(1):90–5. https://doi.org/10.1002/pbc.
23277 PMID: 21837771
2. Binz P, Bodmer N, Leibundgut K, Teuffel O, Niggli FK, Ammann RA. Different fever definitions and the
rate of fever and neutropenia diagnosed in children with cancer: a retrospective two-center cohort
study. Pediatric blood & cancer. 2013; 60(5):799–805. https://doi.org/10.1002/pbc.24380 PMID:
23193083
3. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside
combination therapy for fever with neutropenia: systematic review and meta-analysis. Bmj. 2003; 326
(7399):1111. https://doi.org/10.1136/bmj.326.7399.1111 PMID: 12763980
PLOS ONE Bacteremia in pediatric cancer patients and fever in neutropenia
PLOS ONE | https://doi.org/10.1371/journal.pone.0246654 February 12, 2021 12 / 14
4. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on
gram-positive and resistant bacteria. Clinical infectious diseases: an official publication of the Infectious
Diseases Society of America. 1999; 29(3):490–4. https://doi.org/10.1086/598620 PMID: 10530434
5. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, et al. Guideline for
the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell
Transplantation Recipients: 2017 Update. Journal of clinical oncology: official journal of the American
Society of Clinical Oncology. 2017; 35(18):2082–94. https://doi.org/10.1200/JCO.2016.71.7017 PMID:
28459614
6. National Collaborating Centre for Cancer. Neutropenic Sepsis: Prevention and Management of Neutro-
penic Sepsis in Cancer Patients. London: National Institute for Health; Clinical Excellence (UK)2012.
7. Diagnostik und Therapie bei Kindern mit onkologischer Grunderkrankung, Fieber und Granulozytopenie
(mit febriler Neutropenie) ausserhalb der allogenen Stammzelltransplantation AWMF S2K Leitlinie
(AWMF-Reigsternummer 048/14, finale Version 23.01.2016) n.d.
8. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for
the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious dis-
eases society of america. Clinical infectious diseases: an official publication of the Infectious Diseases
Society of America. 2011; 52(4):e56–93.
9. El-Mahallawy HA, El-Wakil M, Moneer MM, Shalaby L. Antibiotic resistance is associated with longer
bacteremic episodes and worse outcome in febrile neutropenic children with cancer. Pediatric blood &
cancer. 2011; 57(2):283–8. https://doi.org/10.1002/pbc.22926 PMID: 21671364
10. Ariffin H, Navaratnam P, Mohamed M, Arasu A, Abdullah WA, Lee CL, et al. Ceftazidime-resistant Kleb-
siella pneumoniae bloodstream infection in children with febrile neutropenia. Int J Infect Dis. 2000; 4
(1):21–5. https://doi.org/10.1016/s1201-9712(00)90061-4 PMID: 10689210
11. von Allmen AN, Zermatten MG, Leibundgut K, Agyeman P, Ammann RA. Pediatric patients at risk for
fever in chemotherapy-induced neutropenia in Bern, Switzerland, 1993–2012. Sci Data. 2018;
5:180038. https://doi.org/10.1038/sdata.2018.38 PMID: 29534058
12. Ammann RA, Bodmer N, Hirt A, Niggli FK, Nadal D, Simon A, et al. Predicting adverse events in chil-
dren with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN
study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;
28(12):2008–14. https://doi.org/10.1200/JCO.2009.25.8988 PMID: 20231680
13. Brack E, Bodmer N, Simon A, Leibundgut K, Kuhne T, Niggli FK, et al. First-day step-down to oral out-
patient treatment versus continued standard treatment in children with cancer and low-risk fever in neu-
tropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatric blood &
cancer. 2012; 59(3):423–30. https://doi.org/10.1002/pbc.24076 PMID: 22271702
14. Agyeman P, Kontny U, Nadal D, Leibundgut K, Niggli F, Simon A, et al. A prospective multicenter study
of microbiologically defined infections in pediatric cancer patients with fever and neutropenia: Swiss
Pediatric Oncology Group 2003 fever and neutropenia study. The Pediatric infectious disease journal.
2014; 33(9):e219–25. https://doi.org/10.1097/INF.0000000000000326 PMID: 24618935
15. Ammann RA, Niggli FK, Leibundgut K, Teuffel O, Bodmer N. Exploring the association of hemoglobin
level and adverse events in children with cancer presenting with fever in neutropenia. PloS one. 2014; 9
(7):e101696. https://doi.org/10.1371/journal.pone.0101696 PMID: 25020130
16. Miedema KG, Winter RH, Ammann RA, Droz S, Spanjaard L, de Bont ES, et al. Bacteria causing bac-
teremia in pediatric cancer patients presenting with febrile neutropenia—species distribution and sus-
ceptibility patterns. Supportive care in cancer: official journal of the Multinational Association of
Supportive Care in Cancer. 2013; 21(9):2417–26. https://doi.org/10.1007/s00520-013-1797-4 PMID:
23579946
17. Nimah MM, Bshesh K, Callahan JD, Jacobs BR. Infrared tympanic thermometry in comparison with
other temperature measurement techniques in febrile children. Pediatric critical care medicine: a journal
of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical
Care Societies. 2006; 7(1):48–55. https://doi.org/10.1097/01.pcc.0000185476.35550.b2 PMID:
16395075
18. Schlapbach LJ, Aebi C, Otth M, Luethy AR, Leibundgut K, Hirt A, et al. Serum levels of mannose-bind-
ing lectin and the risk of fever in neutropenia pediatric cancer patients. Pediatric blood & cancer. 2007;
49(1):11–6. https://doi.org/10.1002/pbc.21097 PMID: 17143875
19. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous
empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer che-
motherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for
Research and Treatment of Cancer. The New England journal of medicine. 1999; 341(5):312–8. https://
doi.org/10.1056/NEJM199907293410502 PMID: 10423465
PLOS ONE Bacteremia in pediatric cancer patients and fever in neutropenia
PLOS ONE | https://doi.org/10.1371/journal.pone.0246654 February 12, 2021 13 / 14
20. Buetti N, Atkinson A, Kottanattu L, Bielicki J, Marschall J, Kronenberg A, et al. Patterns and trends of
pediatric bloodstream infections: a 7-year surveillance study. Eur J Clin Microbiol Infect Dis. 2017; 36
(3):537–44. https://doi.org/10.1007/s10096-016-2830-6 PMID: 27885442
21. Petty LA, Sokol EA, Bartlett AH, McNeer JL, Alexander KA, Pisano J. Repeated Blood Cultures in Pedi-
atric Febrile Neutropenia: Would Following the Guidelines Alter the Outcome? Pediatric blood & cancer.
2016; 63(7):1244–9. https://doi.org/10.1002/pbc.25965 PMID: 26970419
22. Solis Y, Alvarez AM, Fuentes D, de la Barra D, Aviles CL, Becker A, et al. [Bloodstream infections in
children with cancer and high risk fever and neutropenia episodes in six hospitals of Santiago, Chile
between 2004 and 2009]. Revista chilena de infectologia: organo oficial de la Sociedad Chilena de
Infectologia. 2012; 29(2):156–62.
23. Neemann K, Yonts AB, Qiu F, Simonsen K, Lowas S, Freifeld A. Blood Cultures for Persistent Fever in
Neutropenic Pediatric Patients Are of Low Diagnostic Yield. Journal of the Pediatric Infectious Diseases
Society. 2016; 5(2):218–21. https://doi.org/10.1093/jpids/piu145 PMID: 27199474
24. Weisman LE. Coagulase-negative staphylococcal disease: emerging therapies for the neonatal and
pediatric patient. Curr Opin Infect Dis. 2004; 17(3):237–41. https://doi.org/10.1097/00001432-
200406000-00011 PMID: 15166827
25. Lee JH, Kim SK, Han SB, Lee JW, Lee DG, Chung NG, et al. Increase in Antibiotic-Resistant Gram-
Negative Bacterial Infections in Febrile Neutropenic Children. Infect Chemother. 2016; 48(3):181–9.
https://doi.org/10.3947/ic.2016.48.3.181 PMID: 27659431
26. Greenberg D, Moser A, Yagupsky P, Peled N, Hofman Y, Kapelushnik J, et al. Microbiological spectrum
and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology
patients: comparison between two consecutive time periods with use of different antibiotic treatment
protocols. International journal of antimicrobial agents. 2005; 25(6):469–73. https://doi.org/10.1016/j.
ijantimicag.2005.01.020 PMID: 15890499
27. Han SB, Jung SW, Bae EY, Lee JW, Lee DG, Chung NG, et al. Extended-spectrum β-lactamase-pro-
ducing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children. Microb
Drug Resist. 2015; 21(2):244–51. https://doi.org/10.1089/mdr.2014.0092 PMID: 25398058
PLOS ONE Bacteremia in pediatric cancer patients and fever in neutropenia
PLOS ONE | https://doi.org/10.1371/journal.pone.0246654 February 12, 2021 14 / 14
